Fc-Fusion Proteins: A Growing Class of Therapeutics - Austropa ...

Recommendations

Info

Approaches to Debottleneck Protein ProductionLimited integration è expression vector designLimited transcription è codon optimization, toxic motifsLimited translation è culture conditions, mediaoptimization, cell engineeringCONFIDENTIAL
Effect <strong>of</strong> Media and Culture Conditions on BCFBlood clotting factorTiter (mg/L)350300250200150100500BatchFed-BatchFed-Batch switch to 32°C at day 50 1 2 3 4 5 6 7 8 9 10 11 12Run time [days]Clone-dependent è more effort incell line selectionCONFIDENTIAL
Page 6 and 7: Design of CD4IgG• Assembles into
Page 8 and 9: 34 Therapeutic monoclonal antibody/
Page 10 and 11: Potential production issues with Fc
Page 12 and 13: Presentations• Engineering a CHO
Page 14 and 15: Cell Line Development Process Desir
Page 16 and 17: How Components Impact on Yield• E
Page 18 and 19: CONFIDENTIAL10VHc250 AntibodyCombin
Page 22 and 23: Inefficient Processing and Secretio
Page 24 and 25: Chaperones operating in the ER…So
Page 26 and 27: Metabolically Engineered CellsLow-P
Page 28 and 29: Volumetric Productivity in Fed Batc
Page 30 and 31: ConclusionsBottlenecks are specific
Page 32 and 33: Bioprocessing Challenges ofFusion P
Page 34 and 35: First Example: Fc-Fusion + mFactor
Page 36 and 37: Temper Expectations on Expression R
Page 38 and 39: Fusion Proteins Tend to AggregateCo
Page 40 and 41: Other Strategies for Protein A Elut
Page 42 and 43: Removal of Aggregates -- SEC• Whe
Page 44 and 45: Even Nanofiltration Can be Problema

Fc-Fusion Proteins: A Growing Class of Therapeutics - Austropa ...

Create successful ePaper yourself

Delete template?

Save as template?